PAULA DAWSON: Open Payments
NPI 1881310449 · LA VISTA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,288 in 71 payments from 21 companies in 2025. Trend: 2023 $0 · 2024 $896 · 2025 $1,288
Food & beverage: $1,288
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $331 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $149 |
| Axsome Therapeutics, Inc. | 6 | $112 |
| Novo Nordisk Inc | 4 | $77 |
| Sumitomo Pharma America, Inc. | 4 | $73 |
| Lilly USA, LLC | 3 | $62 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $51 |
| Vanda Pharmaceuticals Inc. | 3 | $51 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $50 |
| Lundbeck LLC | 3 | $45 |
Products named: VRAYLAR, CAPLYTA, Auvelity, UBRELVY, QULIPTA, GEMTESA, MOUNJARO, Wegovy.
Industry payments across NE — which companies pay providers there.
